237 451

Cited 4 times in

Staphylococcus 균종과 그람음성 간균에 대한 Arbekacin의 시험관내 항균력

Other Titles
 In Vitro Activity of Arbekacin Against Clinical Isolates of Staphylococcus speciesand Gram-negative Bacilli 
Authors
 이종한  ;  김창기  ;  정윤섭  ;  이경원  ;  용동은  ;  염종화  ;  이혁민  ;  노경호 
Citation
 KOREAN JOURNAL OF LABORATORY MEDICINE , Vol.27(4) : 292-297, 2007 
Journal Title
 KOREAN JOURNAL OF LABORATORY MEDICINE 
ISSN
 1598-6535 
Issue Date
2007
Abstract
Background :Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli. Method :The strains were isolated from clinical specimens of patients at Severance Hospital in 2003. Antimicrobial susceptibility was tested by the Clinical and Laboratory Standards Institute agar dilution method. The following arbekacin breakpoints were used: susceptible, 4 g/ mL; and resistant, 16 g/mL . Result :All isolates of staphylococci tested were inhibited by 4 g/mL of arbekacin, regardless of their methicillin susceptibility. The MIC90s of arbekacin, 1-4 g/mL, were 8->32-fold and >32-128-fold lower than those of amikacin and gentamicin, respectively. The resistance rates of MRSA, methicillin-susceptible S. aureus, methicillin-resistant coagulase-negative staphylococci (CNS) and methicillin-susceptible CNS were 0% to arbekacin, 0-54% to amikacin, and 24-79% to gentamicin. The MIC90s of arbekacin for Escherichia coli and Citrobacter freundii, 1 g/mL and 16 g/mL, were 2-4-fold and 8-16-fold lower than those of amikacin and gentamicin, respectively. However, The MIC90s of arbekacin for other species of gram-negative bacilli, 64->128 g/mL, were similar to those of other aminoglycosides. Conclusion :Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. coli, C. freundii and some other gram-negative bacilli were also susceptible to arbekacin.
Files in This Item:
T200700451.pdf Download
DOI
10.3343/kjlm.2007.27.4.292
Appears in Collections:
5. Research Institutes (연구소) > Research Institute of Bacterial Resistance (세균내성연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chang Ki(김창기)
Yum, Jong Hwa(염종화)
Yong, Dong Eun(용동은) ORCID logo https://orcid.org/0000-0002-1225-8477
Lee, Kyungwon(이경원) ORCID logo https://orcid.org/0000-0003-3788-2134
Chong, Yun Sop(정윤섭)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/96950
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse